多层血流调节器支架治疗德国复杂主动脉瘤的早期与中期结果
德国回顾性研究纳入40例复杂主动脉瘤患者,使用多层血流调节器(MFM)行腔内修复,技术成功率95%,30天死亡率2.5%,平均随访12.9个月,1年免于破裂率86%、免于再干预率75%。作者认为在紧急病例中技术可行,中期结果可接受,可能需要再干预以扩大疗效。
要点
- 40例复杂主动脉瘤患者使用MFM,技术成功率95%(38/40),30天死亡率2.5%。
- 平均随访12.9个月,1年生存率70%,免于破裂率86%,免于再干预率75%。
- 随访中4例(10%)发生动脉瘤囊破裂,10例(25%)接受再干预。
核心结论
- 在紧急病例中,使用MFM对复杂主动脉瘤进行腔内治疗在死亡率和并发症方面似乎技术可行,30天结果中等,中期结果可接受。
- 可能需要再干预以扩大疗效。
研究设计与样本
- 德国回顾性研究,2009年至2014年间在29家医院共61例腹主动脉瘤、胸腹主动脉瘤或胸主动脉瘤患者接受MFM支架,其中14家医院40例患者数据可用于分析。
- 40例患者平均年龄73.4±11.2岁,男性72.5%(29/40),平均主动脉瘤直径60.3±16.6 mm。
- 37例(93%)患者为紧急治疗;12例(12/40 [30%])因动脉瘤直径>65 mm而在说明书外使用。
- 共使用69枚MFM支架(1.7枚/患者)。
主要发现
- 技术成功率95%(38/40);术后无脊髓缺血、肾功能恶化、卒中或肠缺血,除1例因早期支架移位发生多器官衰竭。
- 术中死亡率为0%,30天死亡率为2.5%;平均随访12.9个月(±14.9个月)。
- 1个月、6个月和12个月生存率分别为97%、78%和70%;免于失效模式(I型或II型)分别为97.5%、88%和86%;内脏血管通畅率为99.3%(155/156可用)。
- 随访中4例(4/39 [10%])发生动脉瘤囊破裂,10例(10/39 [25%])接受再干预;1个月、6个月和12个月免于破裂分别为97.5%、96%和86%,免于再干预分别为100%、84%和75%。
关键数值与推荐
- 原文未报告
临床怎么用
- 作者认为,在紧急病例中,MFM用于复杂主动脉瘤的腔内治疗在死亡率和并发症方面似乎技术可行,30天结果中等,中期结果可接受。
- 作者指出可能需要再干预以扩大疗效。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to assess the early and midterm outcomes of endovascular repair of complex aortic aneurysm cases using the Multilayer Flow Modulator (MFM; Cardiatis, Isnes, Belgium) endograft in Germany. METHODS: A retrospective study including patients presenting with abdominal aortic aneurysm (AAA), thoracic aortic aneurysm, or thoracoabdominal aortic aneurysm treated with the MFM was conducted in Germany. Mortality and morbidity (in terms of spinal cord ischemia, visceral ischemia, and stroke) at 30 days postoperatively were evaluated. In addition, during follow-up, freedom from reintervention, rupture, and failure mode were also assessed. RESULTS: Between 2009 and 2014, a total of 61 patients with AAA, thoracoabdominal aortic aneurysm, or thoracic aortic aneurysm were treated with the MFM endograft in 29 hospitals around Germany. However, data of 40 patients with a mean age of 73.4 ± 11.2 years (72.5% male; 29/40) and mean aortic aneurysm diameter of 60.3 ± 16.6 mm from 14 hospitals were available for this retrospective study. Thirty-seven (93%) patients were treated urgently. In 12 cases (12/40 [30%]), patients were treated outside instructions for use because of aortic aneurysm diameter >65 mm. A total of 69 MFM stents were used (1.7/patient). The technical success rate was 95% (38/40). Postoperatively, no patient presented with spinal cord ischemia, renal function deterioration, stroke, or intestinal ischemia, except for one patient who developed multiorgan failure because of early stent migration. The intraoperative and 30-day mortality rate was 0% and 2.5%, respectively. The mean follow-up was 12.9 months (±14.9 months), with a survival rate at 1 month, 6 months, and 12 months of 97%, 78%, and 70%, respectively. Freedom from failure mode (type I or II) at 1 month, 6 months, and 12 months was 97.5%, 88%, and 86%, respectively, and visceral vessel patency was 99.3% (155/156 available). During follow-up, 4 patients (4/39 [10%]) had an aneurysm sac rupture and 10 (10/39 [25%]) underwent a reintervention. Freedom from rupture and freedom from reintervention at 1 month, 6 months, and 12 months were 97.5% and 100%, 96% and 84%, and 86% and 75%, respectively. CONCLUSIONS: The use of the MFM for endovascular treatment of complex aortic aneurysm in urgent cases appears to be technically feasible in terms of mortality and morbidity, with moderate 30-day and acceptable midterm outcomes. Reinterventions may be needed to expand the utility of outcomes.
引用
- Ibrahim W, Spanos K, Gussmann A, et al. Early and midterm outcome of Multilayer Flow Modulator stent for complex aortic aneurysm treatment in Germany. J Vasc Surg. 2018. PMID: 29602471. doi:10.1016/j.jvs.2018.01.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。